Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Orion Office REIT Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Orion Office REIT Inc trades at $2.72 (market cap $156.87M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 59.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.91% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | ONL | |
|---|---|---|
Market Cap | $9.39B | $156.87M |
Sector | Health | Real Estate |
52-Week High | $356.25 | $3.04 |
52-Week Low | $241.71 | $1.93 |
Enterprise Value | $9.14B | $573.80M |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
ONL trades at $2.82, up 8.46% today, with strong technical indicators showing bullish momentum. The stock shows mixed fundamentals with a low P/B ratio of 0.25 but negative profitability metrics including -65.66% net income margin. Recent Q2 2026 earnings beat expectations with EPS of $0.42 versus -$0.07 forecast, while the company continues strategic portfolio repositioning and maintains a $0.02 dividend payment.
Outlook remains cautious due to persistent net losses and declining revenue trends, though analyst consensus is evenly split between Buy and Hold ratings. Key risks include high debt levels with 39.68% debt-to-asset ratio and ongoing negative cash flow from operations. The technical bullish signal suggests short-term upside potential despite fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
